Everything below concerns WADA prohibited list. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
The adaptor hypothesis was framed to explain how information could be extracted from a nucleic acid and used to put together a string of amino acids in a specific sequence, that sequence being determined by the nucleotide sequence of the nucleic acid (DNA or RNA) template. Crick proposed that each amino acid is first attached to its own specific "adaptor" piece of nucleic acid (in an enzyme-catalysed reaction). The order of assembly of the amino acids is then determined by a specific recognition between the adaptor and the nucleic acid which is serving as the informational template. In this way the amino acids could be lined up by the template in a specific order. Coupling between adjacent amino acids would then lead to the synthesis of a polypeptide whose sequence is determined by the template nucleic acid.
The Fatherland Front participated in the elections with a common list and separate ballots for the member parties. While the Communists obtained an absolute majority in the parliament, the People's Union Zveno had an extremely poor result of about 70,000 votes, and its leaders, including Georgiev himself, became deputies only thanks to the common list of the Fatherland Front.
Verucerfont (GSK-561,679) is a drug developed by GlaxoSmithKline which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors CRH-1 and CRH-2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress. Verucerfont blocks the CRH-1 receptor, and so reduces ACTH release following chronic stress. It is under investigation as a potential treatment for alcoholism, as chronic stress is often a factor in both development of alcoholism and relapse in recovering alcoholics. It has shown promising results in animal studies. However, human trials have shown that while the neuroendocrine effects translate from animal models, the alcohol anti-craving effects do not.
== Applications == NMR is extensively used in medicine in the form of magnetic resonance imaging. NMR is widely used in organic chemistry and industrially mainly for analysis of chemicals. The technique is also used to measure the ratio between water and fat in foods, monitor the flow of corrosive fluids in pipes, or to study molecular structures such as catalysts.
== Mechanism of action == 2,6‑Dichloro‑1,4-benzoquinone (DCBQ) exerts cytotoxic effects primarily through depletion of cellular glutathione (GSH). GSH is a major intracellular antioxidant that protects cells by neutralizing reactive oxygen and nitrogen species (ROS and RNS). Because of this role, cellular GSH levels are commonly used as an indicator of oxidative stress. A decrease in GSH disrupts the cellular redox balance and can act as an important signal that triggers the activation of cell death pathways. The reducing capacity of GSH is therefore essential for maintaining cellular survival. DCBQ belongs to a group of halobenzoquinones (HBQs), four of which have been shown to be cytotoxic to T24 human bladder carcinoma cells. These compounds induce oxidative stress through the generation of reactive oxygen species, which can cause oxidative damage to cellular components such as DNA and proteins. In the presence of DCBQ, intracellular GSH levels are inversely correlated with ROS production and glutathione S‑transferase (GST) activity. By depleting cellular GSH, HBQs promote increased ROS formation and stimulate GST activity as part of the cellular response to oxidative stress.
Sources: en.wikipedia.org
In May 2025, Moore signed into law a bill that would establish a $25 million grant fund to expand abortion access for uninsured or underinsured individuals, funded a $1 surcharge on insurance plans sold under the Affordable Care Act. The law made Maryland become the first state to use these funds for this purpose. The program was blocked from going into effect by federal health officials in January 2026, who said the program "exceeds permissible use" of the fees collected by the Affordable Care Act. In May 2026, Moore signed into law a bill requiring hospitals to perform abortions in emergency medical situations.
===== UPMC Kane ===== UPMC Kane, formerly known as Kane Community Hospital, is a 31-bed acute care hospital located in Kane, Pennsylvania, that became an affiliate of UPMC Hamot in November 2009. UPMC Kane was fully integrated into the UPMC network on April 1, 2017, and functions as a direct subsidiary of UPMC Hamot.
== Synthesis == First, 2-(o-chlorobenzoylamino)-5-bromo-2-chlorobenzophenone is prepared by acylation of p-bromoaniline with o-chlorobenzoic acid acyl chloride in the presence of a zinc chloride catalyst. This is hydrolysed with aqueous sulfuric acid to yield 2-amino-5-bromo-2'-chlorobenzophenone, which is then acylated with hydrochloride of aminoacetic acid acyl chloride in chloroform to form 2-(aminomethylkarbonylamino)-5-bromo-2-chlorobenzophenone hydrochloride, which is converted to a base with aqueous ammonia and then thermally cyclized to bromodihydrochlorophenylbenzodiazepine (phenazepam). Hydrochloride of aminoacetic acid acyl chloride is prepared by chemical treating glycine with phosphorus pentachloride (PCl5) in chloroform.
To achieve the goal of tissue reconstruction, scaffolds must meet some specific requirements. High porosity and adequate pore size are necessary to facilitate cell seeding and diffusion throughout the whole structure of both cells and nutrients.
Sources: en.wikipedia.org
Gay-Lussac's law refers to two distinct principles in physical chemistry established by Joseph Louis Gay-Lussac: the law of combining volumes (describing gaseous chemical reactions) and the pressure–temperature law (for a gas at constant volume). The latter law was published by Gay-Lussac in 1802, but in the article in which he described his work, he cited earlier unpublished work from the 1780s by Jacques Charles. Consequently, the volume-temperature proportionality is usually known as Charles's law.
Lipton Iced Tea or Lipton Ice Tea a ready to drink tea brand made and distributed by the joint ventures between Unilever and PepsiCo. It is typically sold in five flavours, lemon, peach, mint & lime, mango, and raspberry. Citrus, watermelon, and mixed berry flavours are also available in some regions.
In November 2025, United States President Donald Trump announced a deal with Novo to lower the costs of Ozempic, including monthly prices of about $245 for injectables and $149 for some oral versions for people on Medicare and Medicaid and for those who use his TrumpRx platform. In 2026, new obesity GLP-1 pills were launched, with patients getting their hands on them from Danish drugmaker Novo. Novo filed a federal lawsuit against Eli Lilly and Company in July 2026 in the District of New Jersey, alleging that Eli Lilly engaged in false advertising regarding its weight-loss and diabetes medications. The complaint accuses Lilly of misrepresenting comparative clinical data and omitting key information to gain an unfair advantage in the U.S. anti-obesity medication market.
== Function and Terminology == The “pre-” prefix of preproglucagon indicates that it is composed of proglucagon together with a signal peptide. The signal peptide is a 20 amino acid fragment that signals that the protein needs to be secreted out of the cell. Proglucagon has the “pro-“ prefix because it is a prohormone, which means it is an inactivate precursor that needs to be further modified in order to produce active hormone(s). In particular, proglucagon is cleaved (cut) into different active hormones depending on the organ. Omitting various inactive fragments, preproglucagon is cleaved into the following:
== Chemical structure and properties == Retinyl acetate is the acetate ester of all‑trans‑retinol. Its polyene side chain makes the molecule highly lipophilic and sensitive to photo‑oxidation; antioxidants (e.g., tocopherol) and opaque packaging are therefore used to limit degradation in finished products. The compound melts at ~59 °C and is practically insoluble in water but miscible with edible oils and most organic solvents.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.